Weimin Peng
Overview
Explore the profile of Weimin Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Childress E, Capstick R, Crocker K, Ledyard M, Bender A, Maurer M, et al.
ACS Med Chem Lett
. 2024 Dec;
15(12):2210-2219.
PMID: 39691522
This Letter details our efforts to develop novel, non-acetylene-containing metabotropic glutamate receptor subtype 5 (mGlu) negative allosteric modulators (NAMs) with improved pharmacological properties. This endeavor involved replacing the ether-linked pyrimidine...
2.
Poslunsey M, Wood M, Han C, Stauffer S, Panarese J, Melancon B, et al.
ACS Chem Neurosci
. 2024 Dec;
16(1):95-107.
PMID: 39660766
Herein we detail the of VU0467319 (VU319), an M Positive Allosteric Modulator (PAM) clinical candidate that successfully completed a Phase I Single Ascending Dose (SAD) clinical trial. VU319 () is...
3.
Engers J, Baker L, Chang S, Luscombe V, Rodriguez A, Niswender C, et al.
ACS Chem Neurosci
. 2024 Sep;
PMID: 39316465
Herein, we report structure-activity relationship (SAR) studies to develop novel tricyclic M PAM scaffolds with improved pharmacological properties. This endeavor involved a "tie-back" strategy to replace a 5-amino-2,4-dimethylthieno[2,3-]pyrimidine-6-carboxamide core, which...
4.
Engers J, Bollinger K, Capstick R, Long M, Bender A, Dickerson J, et al.
ACS Chem Neurosci
. 2024 Aug;
15(18):3421-3433.
PMID: 39197083
Herein we report progress toward a backup clinical candidate to the M positive allosteric modulator (PAM) VU319/ACP-319. Scaffold-hopping from the pyrrolo[2,3-]pyridine-based M PAM VU6007477 to isomeric pyrrolo[3,2-]pyridine and thieno[3,2-]pyridine congeners...
5.
Wu J, Wade S, Itani T, Castaigne J, Kloos I, Peng W, et al.
Leuk Lymphoma
. 2024 Jul;
65(11):1609-1622.
PMID: 38975903
To quantify the clinical unmet need of r/r MCL patients who progress on a covalent Bruton tyrosine kinase inhibitor (BTKi), we conducted a systematic review to identify studies that reported...
6.
Salles G, Chen J, Zhang I, Kerbauy F, Wu J, Wade S, et al.
Adv Ther
. 2024 Mar;
41(5):1938-1952.
PMID: 38494543
Introduction: Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) often require multiple lines of treatment and have a poor prognosis, particularly after failing covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy....
7.
Wang M, Munoz J, Goy A, Locke F, Jacobson C, Hill B, et al.
J Clin Oncol
. 2022 Jun;
41(3):555-567.
PMID: 35658525
Purpose: Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the...
8.
Petersohn S, Salles G, Wang M, Wu J, Wade S, Simons C, et al.
J Med Econ
. 2022 May;
25(1):730-740.
PMID: 35611697
Aims: The objective of this study is to estimate the cost-effectiveness of KTE-X19 versus standard of care (SoC) in the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)...
9.
Moehle M, Bender A, Dickerson J, Foster D, Qi A, Cho H, et al.
ACS Pharmacol Transl Sci
. 2021 Aug;
4(4):1306-1321.
PMID: 34423268
Nonselective antagonists of muscarinic acetylcholine receptors (mAChRs) that broadly inhibit all five mAChR subtypes provide an efficacious treatment for some movement disorders, including Parkinson's disease and dystonia. Despite their efficacy...
10.
Xiao Y, Liu J, He D, Chen S, Peng W, Hu X, et al.
ACS Appl Mater Interfaces
. 2021 Aug;
13(32):38266-38277.
PMID: 34374273
With the battery-type anode and capacitor-type cathode, lithium-ion capacitors (LICs) are expected to exhibit both high energy and high power density but suffer from the mismatch of the electrode reaction...